| Symbol | CRBP |
|---|---|
| Name | CORBUS PHARMACEUTICALS HOLDINGS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 500 RIVER RIDGE DRIVE,SECOND FLOOR, NORWOOD, Massachusetts, 02062, United States |
| Telephone | +1 617 963-0100 |
| Fax | — |
| — | |
| Website | https://www.corbuspharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001595097 |
| Description | Corbus Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for endocannabinoid or immune system. The companys lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. Additional info from NASDAQ: |
Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026
Read moreCorbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701
Read moreCorbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701
Read more(99% Neutral) CORBUS PHARMACEUTICALS HOLDINGS, INC. (CRBP) Announces Executive Changes
Read moreNew Form DEFA14A - Corbus Pharmaceuticals Holdings, Inc. <b>Filed:</b> 2026-04-16 <b>AccNo:</b> 0001193125-26-159074 <b>Size:</b> 29 KB
Read more(75% Positive) CORBUS PHARMACEUTICALS HOLDINGS, INC. (CRBP) Provides Update on study for 240 obese
Read moreCorbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity
Read moreCorbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity
Read more(90% Positive) CORBUS PHARMACEUTICALS HOLDINGS, INC. (CRBP) Provides Update on path for CRB-701
Read moreCorbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical Cancer
Read more